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Abstract 
Background: Older people experience poorer outcomes from colon cancer.  We examined if 
treatment for colon cancer was related to age and if inequalities changed over time. 
Methods: Data from the UK population-based Northern and Yorkshire Cancer Registry on 31,910 
incident colon cancers (ICD10 C18) diagnosed 1999-2010 were obtained. Likelihood of receipt of: 1) 
cancer-directed surgery, 2) chemotherapy in surgical patients, 3) chemotherapy in non-surgical 
patients by age, adjusting for sex, area deprivation, cancer stage, co-morbidity and period of 
diagnosis was examined. 
Results: Age-related inequalities in treatment exist after adjustment for confounding factors. 
Patients aged 60-69, 70-79 and 80+ years were significantly less likely to receive surgery than those 
aged <60 years (multivariable ORs [95% CI] 0.84 [0.74, 0.95], 0.54 [0.48, 0.61] and 0.19 [0.17, 0.21] 
respectively). Age-related differences in receipt of surgery and adjuvant chemotherapy (but not 
chemotherapy in non-surgical patients) narrowed over time for the ‘younger old’ (aged less than 80 
years) but did not diminish for the oldest patients.   
Conclusions: Age inequality in treatment of colon cancer remains after adjustment for confounders, 
suggesting age remains a major factor in treatment decisions. Research is needed to better 
understand the cancer treatment decision-making process, and how to influence this, for older 
patients.  
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Summary box 
What is already known on this subject? 
• Older individuals have poorer survival from colon cancer than younger individuals. 
• Inequalities in access to appropriate colon cancer treatment might account for this 
poorer survival. 
 
What does this study add? 
• Older age is associated with lower likelihood of receiving colon cancer directed surgery 
and adjuvant therapy, and greater likelihood of receiving no cancer directed treatment, 
after adjustment for confounding factors. 
• There is evidence that the treatment gap between youngest patients and the ‘younger 
old’ decreased between 1999 and 2010. 
• There was no narrowing of the treatment gap between the youngest patients and the 
‘older old’ during this period. 
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Introduction 
Colorectal cancer is the third most commonly diagnosed cancer in men and women in the UK1 and 
globally2. Survival from colon cancer worldwide is worse in those aged 65 years and older3, despite 
more than 70% of cases occurring in this age group1. In addition, a survival deficit has been identified 
in the UK compared to countries with the highest cancer survival (Australia, Canada, Norway & 
Sweden). Both 1 and 5 year survival for colorectal cancer are 8-10% lower in the UK compared to 
countries with the highest survival, and this increases to a 10-15% difference for those aged 65 years 
and older3. There is evidence that the gap in colorectal cancer survival between older and younger 
patients widened between 1988-90 and 1997-99 across Europe in women, although narrowed 
slightly during the same time period in men4. There was lower survival in the UK compared to five 
other countries with similar levels of healthcare access, included in the International Cancer 
Benchmarking Partnership, and this was more pronounced in older (aged 70-99 years) patients5. 
Age-related variation in survival is much less marked in the United States than in Europe and has 
been attributed to earlier diagnosis and more aggressive treatment in the US6. It has been suggested 
that in several countries, including the UK, elderly cancer patients are under-treated compared to 
younger patients7-9, and that this unequal access to treatment in practice, despite universal access in 
theory, accounts for at least some of the reported survival difference5.   
Previous work suggests that elderly patients are significantly less likely to receive adjuvant therapy 
for colon cancer10,11. It has been observed that elderly patients who survive one year after diagnosis 
of cancer have a similar 5-year prognosis to middle-aged patients4, suggesting that elderly patients 
who are in sufficiently good health to withstand treatment can derive similar benefits to younger 
patients. Determining the best course of cancer treatment for elderly people, a population that is 
heterogeneous in terms of health status and degree of frailty, is difficult for clinicians12. 
Comorbidities, poorer health status and cancer stage at diagnosis, as well as patient preferences, 
5 
 
may be valid reasons for not offering aggressive treatment to frail, older patients13. However, many 
epidemiological studies of patterns of treatment by age fail to account for these factors. 
A better understanding of age-related inequalities in treatment of colon cancer would help to inform 
interventions to improve cancer control. We undertook a population-based study to investigate if 
there are age-related inequalities in colon cancer care in the North of the UK, taking into account co-
morbidity and other confounders and, if so, if these inequalities have changed over time.  
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Methods 
Data sources. Data on age, sex, area deprivation (as a proxy for socioeconomic status (SES)), year of 
diagnosis, tumour site and stage and treatments received (cancer-directed surgery and 
chemotherapy) were obtained for all patients diagnosed with colon cancer (ICD10 C18) between 1 
January 1999 and 31 December 2010 from the population-based Northern and Yorkshire Cancer 
Registry (NYCRIS). NYCRIS covers a population of 6.8 million people. Hospitals mandatorily report 
cases of cancer directly to NYCRS. Extensive quality assurance of the register is performed14. 
Information on treatments received until 31 December 2011 was available (i.e. 12 months after the 
latest date of diagnosis). Each record was linked to UK National Health Service (NHS) Hospital 
Episode Statistics (HES) data to provide information on comorbidities. All admissions, outpatient 
appointments and A&E attendances at NHS hospitals in England are recorded in HES data. NYCRIS 
supplied the linked and anonymised data to the authors.  
Outcome variables. The outcome variables of interest were chosen to reflect current colon cancer 
treatment guidelines15,16: receipt of cancer-directed surgery compared to no cancer-directed surgery 
(n=31,910 patients included in the analysis), receipt of chemotherapy in surgical patients (n=24,263), 
receipt of chemotherapy in non-surgical patients (n=7,647) and receipt of no cancer-directed 
treatment (i.e. no surgery, chemotherapy or radiotherapy; n=31,910).  
Explanatory variables. Age at diagnosis was categorised into <60, 60-69, 70-79 and 80+ years. Area 
deprivation was measured using the rank of the income domain of the Index of Multiple Deprivation 
(IMD), grouped into quintiles, based on the distribution across England, with quintile 1 representing 
the most affluent areas and quintile 5 the highest level of deprivation17. Year of diagnosis was 
categorised into three equal sized groups for ease of presentation and interpretation: 1999-2002, 
2003-2006, 2007-2010. Cancer stage was assigned using the TNM staging system18 and categorised 
as I, II, III, IV, unstaged or staged post-treatment. NYCRIS provided a weighted comorbidity score 
based on the Charlson comorbidity index (CCM)19, which provides a count of the number of relevant 
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in-patent admissions (excluding metastatic cancer) recorded in HES data in the time period 3-18 
months prior to the colon cancer diagnosis. The comorbidity score was categorised as 0, 1-2 or 3+ 
comorbid conditions resulting in an in-patient episode for ease of interpretation. 
Statistical analyses. Cases registered on the basis of a death certificate only were excluded (n=495), 
In the remaining cases, the distribution of receipt of cancer-directed treatment (surgery, 
chemotherapy in surgical patients, chemotherapy in non-surgical patients and no treatment) by age, 
sex, SES, period of diagnosis, stage and CCM was examined. As chemotherapy is not an appropriate 
treatment in early stage colon cancer analyses were repeated, restricted to Stage III and IV cancers. 
Univariable and multivariable logistic regression models were used to examine the likelihood of 
receipt of each of the treatment outcomes by age group with and without adjustment for covariates. 
Trends in likelihood of receipt of treatment by age over time were examined. Interaction between 
age and time period of diagnosis was tested by fitting a cross-product term and comparing, using the 
likelihood ratio test, the model with the cross-product term and nested model without the cross-
product term to test if there was a significant interaction . For ease of interpretation, the results 
presented here show risk estimates for age group, stratified by period of diagnosis.  Stata v14.0 
(StataCorp, College Station, TX, USA) was used for all analyses. 
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Results 
The analysis included 31,910 patients with incident colon cancer. There was an increase of cases 
over time. Almost two-thirds (63%) of patients were aged 70 years or older at diagnosis; a slightly 
higher proportion were men (52%) than women (Table 1).  
[Table 1 here] 
Receipt of cancer-directed surgery. There was a strong inverse association between age group and 
the odds ratio for receiving surgery which became even stronger after adjustment for the covariates 
(table 2);  compared to the <60 years age group the multivariable odds ratios were (OR= 0.84, 95% CI 
0.74 to 0.95; 0.54, 0.48 to 0.61 and 0.19, 0.17 to 0.21, respectively) (Table 2). When the analyses 
were restricted to patients with stage I-III cancers, almost all (98.9%) of patients received surgery. 
Those in the oldest age group (80+ years) with stage I-III cancers were significantly less likely to 
receive surgery than those in the <60 years age group (OR=0.40, 95% CI 0.25 to 0.64). Overall, the 
likelihood of receiving surgery was lower in the two more recent time periods than in the period 
1999-2002 but the 2006-2010 effect markedly attenuated after adjustment and was consistent with 
chance. There was no gender effect but patients from poorer areas were less likely to receive 
surgery. Co-morbidity was associated with a reduced odds of surgery. 
[Table 2 here] 
Receipt of chemotherapy in surgical patients. Similar age patterns in receipt of chemotherapy were 
seen, although the gradient was even more extreme (Table 3). The likelihood of surgical patients 
receiving chemotherapy increased over time in a dose-response pattern. Men and patients with 
higher stage cancer were more likely to get chemotherapy whilst area deprivation was associated 
with a reduced likelihood. When analyses were repeated, restricted to Stage III and IV cancers, to 
take into account that chemotherapy is not appropriate for early stage cancers, similar results were 
found. 
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[Table 3 here] 
Receipt of chemotherapy in non-surgical patients. Increasing age was also strongly associated with 
reduced likelihood of receiving chemotherapy alone (OR= 0. 43, 95% CI 0.35 to 0.52; 0.20, 0.17 to 
0.24 and 0.03, 0.02 to 0.04 for the 60-69, 70-79 and 80+ year age groups respectively for the fully 
adjusted model) (Table 4). Other covariates showed the same pattern as for chemotherapy amongst 
surgical patients with, again, a marked period effect. Similar results were found when only patients 
with stage III and IV cancers, for whom chemotherapy is recommended, were included in the 
analysis. 
[Table 4 here] 
Receipt of no treatment. Age inequalities were found in likelihood of not receiving any treatment 
(Web Table 1). The odds ratio for receipt of no treatment in those aged 60-69 years was 1.98 (95% CI 
1.69 to 2.32) increasing to 15.4 (13.2 to 17.9) in those aged 80+ years, in the fully adjusted model.  
Time trends in colon cancer treatment 
Figure 1a shows that the difference in the odds ratios for receipt of surgery for patients aged 60-69 
years and 70-79 years compared to those aged <60 years stratified by time period diminished over 
time. However, the change in the odds ratio for patients aged 80+ years was much less marked 
(OR=0.23, 0.18 to 0.29; 0.19, 0.15 to 0.24 and 0.16, 0.13 to 0.20 for the three time periods 
respectively).  
Significant interactions were found between age and period of diagnosis for receipt of surgery 
(p=0.010) and receipt of chemotherapy in surgical (p=0.001), but not in non-surgical (p=0.807), 
patients, suggesting that the relationship between receipt of treatment and age has changed over 
time. 
 [Figure here] Odds ratios for receipt of colon cancer directed treatment by age group, over time, 
adjusted for sex, deprivation, stage and comorbidity 
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In all time periods, surgical patients in the older age groups remained less likely to receive 
chemotherapy than those in the <60 years group (Figure 1b). However, the difference in the odds 
ratios was smaller in 2007-2010 than in 1999-2002 for those in the 60-69 year and 70-79 year age 
groups. There was no change in the 80+ year age group.  
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Discussion 
Main findings. Age inequalities in the receipt of colon cancer-directed surgery, chemotherapy in 
surgical patients and chemotherapy in non-surgical patients were apparent in this population-based 
registry study, after adjustment for factors likely to be associated with the appropriateness of 
providing treatment, including stage and comorbidity. These differences persisted over time. We 
identified an interaction between age and time period of diagnosis associated with receipt of 
treatment. This suggested a narrowing of the treatment gap during the period 1999-2010 between 
those aged <60 years and those aged less than 80 years, but no change in the treatment gap 
between those aged <60 years and the oldest (aged 80 years and older) patients.    
Strengths of this study. The strengths of this study are the use of a population-based registry, linked 
to NHS HES data. The NYCRIS has been found to have excellent population coverage20. This meant 
we have robust data on cases of colon cancer, treatment received and information on potential 
confounding factors. In contrast to many other studies that have examined the relationship between 
age and receipt of treatment for colon cancer and failed to adjust for comorbidity, data on 
comorbidity was available for patients included in this study.  
Weaknesses of this study. Data included in this study were from the north of England. This 
potentially reduces the generalisability of our findings to other settings.  As is common in 
population-based datasets, a notable proportion of patients (14% overall) were unstaged. While this 
could be due to a failure by the registry to record staging information, the low percentage of 
unstaged patients who were treated, and the increase in percentage unstaged by age (24% in the 
80+ age group compared to 8% in the youngest age group), suggests that it is more likely to be 
because these patients were simply too unwell to be staged or treated. Even in this large dataset, 
some sub-groups were relatively small and had few events meaning that the ORs were very small or 
large. We would suggest that the precise risk estimates are not the most important aspect of our 
results; rather the importance lies in the observed pattern in treatment receipt by age.  
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We had information on treatment receipt and, for chemotherapy and radiotherapy this is, in effect, 
whether an individual started a course of treatment.  A limitation is that we did not know whether 
they completed the course; some studies suggest that a significant proportion of patients cannot 
complete treatment due to toxicity21. Although we took account of comorbidity in our analyses, the 
Charlson comorbidity index19 that we used to identify comorbidities, captures information only on 
conditions that require an in-patient stay. It is possible, therefore, that individuals who had a score 
of zero recorded for comorbidity suffered from conditions that would be included in the index, but 
received all their care in primary care or as out-patients. It is also the case that patients with 
different severity of comorbid diseases receive the same score, making it a somewhat crude 
measure. In addition, the CCM was not designed to detect frailty, which is common in older 
individuals and is an important consideration when determining appropriate treatment for colon 
cancer given the  physical burden associated with cancer treatment 12. It is very likely that we have 
underestimated true levels of comorbidity in the study population and failed to fully control for 
confounding by health status. Thus it remains possible that the observed trends in treatment receipt 
by age could be a result – at least in part - of valid clinical decisions based on the patient’s overall 
health and likely ability to withstand treatment. As is usual with registry data, we did not have 
information on whether treatment was given with curative or palliative intent.  In addition, patient 
and family preferences around quality of life can also influence treatment decisions and as this is not 
recorded, we were unable to take these factors into account in our analyses.  
We note that, despite those in the oldest age group with a stage I-III cancer being significantly less 
likely to receive surgery than those in the youngest age group, the number in this age group not 
receiving surgery was small (n=98 patients; 2%) and this might be accounted for by sound clinical 
reasons not to offer surgery to these individuals. 
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Interpretation of findings 
Age-related inequalities in the treatment of colon cancer have previously been reported. In 
particular it has been noted that older people with colon cancer typically receive less adjuvant 
chemotherapy than younger individuals and that the likelihood of receiving adjuvant chemotherapy 
decreases with age22. Putative reasons for this include that evidence for the effectiveness of 
adjuvant chemotherapy in older populations is lacking23. More good quality trials of different 
treatment options in the elderly population upon which evidence-based treatment decisions can be 
made are needed10. Where trials in elderly and frail populations have been attempted, successes 
have been reported. The MRC FOCUS2 trial, an open factorial trial designed to examine reduced 
dose chemotherapy in elderly and frail patients (median age of 74 years) with advanced colorectal 
cancer demonstrated that these patients can be included successfully in randomised controlled trials 
and that age and frailty should not preclude individuals from participation in research24. 
Previous work has suggested that clinicians rely too much on chronological age rather than an 
assessment of biological age and capacity to withstand treatment when making decisions about how 
to treat cancer patients25. The difficulty of, and resources needed for, evaluating the vulnerability of 
elderly people to cancer treatment using the comprehensive geriatric assessment (CGA) have been 
acknowledged. Frailty screening methods to negate the need for the CGA to be used to assess all 
elderly patients have been proposed, but none has yet proved to be satisfactorily able to 
discriminate between those who are robust and should receive standard cancer treatment and 
those who should receive a CGA12. Current guidance remains that all elderly people should receive a 
CGA to inform treatment decisions. 
When we considered whether or not inequalities in receipt of treatment had changed over time we 
found some evidence that the treatment gap between those aged less than 60 years and the 
‘younger old’ (aged less than 80 years) had narrowed to some extent, but that there was no 
evidence of a narrowing of the treatment gap for the oldest old. This might reflect accumulating trial 
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evidence suggesting that the benefit of adjuvant chemotherapy is independent of age, at least up to 
the age of 79 years, but that data on the oldest old is lacking26. In a pooled analysis of adjuvant 
chemotherapy for 3,351 resected colon cancer patients, 14% of included patients were aged 70-79 
years but less than 1% were aged 80 years and older, leading the authors to conclude that 
extrapolation to the oldest age group should be made with caution26.   
Within the UK there is increasing interest in ensuring that the elderly receive appropriate cancer 
treatment. Action for the elderly in cancer was identified as a main priority at the Britain Against 
Cancer Conference in 20137. The National Cancer Equality Initiative, in collaboration with the 
Pharmaceutical Oncology Initiative (NCEI-POI), is a UK-wide effort to challenge ageism in cancer 
care. NCEI-POI seeks to better understand how treatment decisions are made in relation to cancer 
care for older people, to identify how more personalised treatment plans can be developed27. It is 
important that the fitness of the individual patient, the potential benefit they might gain from 
different treatment regimens and patients’, and their family’s’, perspectives on treatment should all 
be taken into account when designing an optimum care plan. 
It was noted in a recent report published by The Royal College of Surgeons of England that existing 
national guidance does not make specific recommendations on how to treat older patients with 
colon cancer, and concluded that ‘all reasonable curative treatment options’ should be explored28.  
Since it is extremely unlikely that the age-disparities in treatment that we have observed can be 
explained by patient or family preference, our data suggest that “all reasonable curative options” are 
still not being explored. It should be acknowledged, however, there remains a lack of good quality 
research into the treatment of elderly colon cancer patients to inform treatment options27. This, 
together with further research to better understand the treatment decision-making process, and 
how to influence this, is urgently needed. 
Whilst the focus of our enquiries was on age equity, our results also demonstrated marked effects by 
area deprivation, and for chemotherapy, there were also gender differences. These are also 
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important in terms of equitable access and appear to have independent effects so that older women 
in deprived areas would be least likely to receive some interventions. 
Colon cancer is common in older people, with 43% of cases diagnosed in people aged 75 years and 
older in the UK between 2009 and 2011)1. Current demographic changes leading to an increasingly 
older population means the number of individuals diagnosed with colon cancer is likely to increase. 
There is a need for work both to identify the most effective treatment for colon cancer in older 
populations and to understand clinicians’ decision making processes to ensure equitable access.  
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Table 1. Demographic and clinical characteristics of cohort with colon cancer (n=31910) 
 n % 
   
Age group   
<60 years 4556 14.3 
60-69 years 7377 23.1 
70-79 years 11086 34.7 
80+ years 8891 27.9 
   
Sex   
Female 15212 47.7 
Male 16698 52.3 
   
Deprivation quintile   
1 (least deprived) 5682 17.8 
2 6150 19.3 
3 5990 18.8 
4 6711 21.0 
5 7377 23.1 
   
Period of diagnosis   
1999-2002 9860 30.9 
2003-2006 10424 32.7 
2007-2010 11626 36.4 
   
Stage   
I 2782 8.7 
II 9107 28.5 
III 7738 24.3 
IV 7712 24.2 
Unstaged 4440 13.9 
Stage PT 131 0.4 
   
CCM   
0 22486 70.5 
1-2 2976 9.3 
3+ 700 2.2 
No HES link 5748 18.0 
   
Treatment   
Any surgery*  24263 76.0 
Surgery + chemotherapy** 7736 31.9 
Chemotherapy alone*** 1589 20.8 
None* 6058 19.0 
*proportion is of all patients with colon cancer (n=31910) 
**proportion is of all patients with colon cancer who had surgery (n=24263) 
***proportion is of all patients with colon cancer who did not have surgery (n=7647)  
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Table 2. Likelihood (odds ratio with 95% CI and p value from logistic regression) of receiving 
cancer-directed surgery* by age, and adjusted for sex, deprivation, time period, stage, and 
comorbidity for patients with colon cancer  
 
 Number (%) 
receiving 
surgery 
Unadjusted 
(n=31910) 
Mutually adjusted 
(n=31910) 
 n % OR 95% CI p OR 95% CI p 
         
Age group 24263 76.0   <0.001   <0.001 
<60 years 3833 84.1 1.00   1.00   
60-69 years 6194 84.0 0.99 0.89, 1.09 0.809 0.84 0.74, 0.95 0.005 
70-79 years 8802 79.4 0.73 0.66, 0.80 <0.001 0.54 0.48, 0.61 <0.001 
80+ years 5434 61.1 0.30 0.27, 0.32 <0.001 0.19 0.17, 0.21 <0.001 
         
Sex 24263 76.0   <0.001   0.052 
Female 11332 74.5 1.00   1.00   
Male 12931 77.4 1.18 1.12, 1.24 <0.001 1.06 0.98, 1.14 0.160 
         
Deprivation quintile 24263 76.0   <0.001   <0.001 
1 (least deprived) 4574 80.5 1.00   1.00   
2 4797 78.0 0.86 0.79, 0.94 0.001 0.91 0.81, 1.04 0.158 
3 4545 75.9 0.76 0.70, 0.83 <0.001 0.76 0.67, 0.86 <0.001 
4 5008 74.6 0.71 0.65, 0.78 <0.001 0.77 0.68, 0.87 <0.001 
5 5339 72.4 0.63 0.58, 0.69 <0.001 0.62 0.55, 0.70 <0.001 
         
Period of diagnosis 24263 76.0   <0.001   0.618 
1999-2002 7837 79.5 1.00   1.00   
2003-2006 7805 74.9 0.77 0.72, 0.82 <0.001 0.80 0.72, 0.87 <0.001 
2007-2010 8621 74.2 0.74 0.69, 0.79 <0.001 0.93 0.84, 1.03 0.146 
         
Stage 24263 76.0   <0.001   <0.001 
I 2751 98.9 1.00   1.00   
II 9028 99.1 1.29 0.85, 1.96 0.235 1.39 0.91, 2.11 0.123 
III 7626 98.6 0.77 0.51, 1.14 0.194 0.76 0.51, 1.13 0.176 
IV 3224 41.8 0.01 0.01, 0.01 <0.001 0.01 0.00, 0.01 <0.001 
Unstaged 1506 33.9 0.01 0.00, 0.01 <0.001 0.01 0.00, 0.01 <0.001 
Stage PT 128 97.7 0.48 0.15, 1.59 0.231 0.34 0.10, 1.15 0.083 
         
CCM 24263 76.0   <0.001   0.041 
0 17851 79.4 1.00   1.00   
1-2 2156 72.5 0.68 0.6130.74 <0.001 0.83 0. 73, 0.95 0.007 
3+ 443 63.3 0.45 0.38, 0.52 <0.001 0.68 0.54, 0.86 0.001 
No HES link 3813 66.3 0.51 0.48, 0.55 <0.001 0.71 0.64, 0.79 <0.001 
         
 
*includes surgery +/- chemotherapy  
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Table 3. Likelihood (odds ratio with 95% CI and p value from logistic regression) of receiving 
chemotherapy in surgical patients by age, and adjusted for sex, deprivation, time period, 
stage and comorbidity for patients with colon cancer 
[Includes only patients who had surgery; n=24,263] 
 Number (%) 
receiving 
chemotherapy 
Unadjusted 
(n=24,263) 
Mutually adjusted 
(n=24,263) 
 n % OR 95% CI p OR 95% CI p 
Age group 7736 31.9   <0.001   <0.001 
<60 years 2264 59.1 1.00   1.00   
60-69 years 2854 46.1 0.59 0.55, 0.64 <0.001 0.54 0.49, 0.60 <0.001 
70-79 years 2356 26.8 0.25 0.23, 0.27 <0.001 0.19 0.17, 0.21 <0.001 
80+ years 262 4.8 0.04 0.03, 0.04 <0.001 0.02 0.02, 0.02 <0.001 
         
Sex 7736 31.9   <0.001   0.126 
Female 3409 30.1 1.00   1.00   
Male 4327 33.5 1.17 1.11, 1.23 <0.001 1.10 1.01, 1.18 0.011 
         
Deprivation quintile 7736 31.9   <0.001   <0.001 
1 (least deprived) 1620 35.4 1.00   1.00   
2 1658 34.6 0.96 0.88, 1.05 0.386 1.08 0.96, 1.20 0.201 
3 1451 31.9 0.86 0.78, 0.93 <0.001 0.92 0.82, 1.03 0.142 
4 1468 29.3 0.76 0.69, 0.82 <0.001 0.81 0.72, 0.91 <0.001 
5 1539 28.8 0.74 0.68, 0.80 <0.001 0.72 0.65, 0.80 <0.001 
         
Period of diagnosis 7736 31.9   <0.001   <0.001 
1999-2002 2235 28.5 1.00   1.00   
2003-2006 2515 32.2 1.19 1.11, 1.28 <0.001 1.36 1.24, 1.49 <0.001 
2007-2010 2986 34.6 1.33 1.24, 1.42 <0.001 1.83 1.66, 2.01  <0.001 
         
Stage 7736 31.9   <0.001   <0.001 
I 39 1.4 1.00   1.00   
II 1442 16.0 13.2 9.59, 18.2 <0.001 17.1 12.5423.6 <0.001 
III 4191 55.0 84.8 61.7, 116.8 <0.001 155.9 109.8, 210.1 <0.001 
IV 1841 57.1 92.6 67.0, 127.9 <0.001 137.3 98.7, 191.0 <0.001 
Unstaged 123 8.2 6.18 4.29, 8.92 <0.001 5.48 3.78, 7.95 <0.001 
Stage PT 100 78.1 248.4 146.9, 419.8 <0.001 216.0 122.5, 380.9 <0.001 
         
CCM 7736 31.9   0.506   <0.001 
0 5935 33.3 1.00   1.00   
1-2 414 19.2 0.48 0.43, 0.53 <0.001 0.53 0.46, 0.61 <0.001 
3+ 59 13.3 0.31 0.23, 0.41 <0.001 0.30 0.21, 0.41 <0.001 
No HES link 1328 34.8 1.07 1.00, 1.15 0.061 0.89 0.79, 0.99 0.043 
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Table 4. Likelihood (odds ratio with 95% CI and p value from logistic regression) of receiving 
chemotherapy in non-surgical patients by age, and adjusted for sex, deprivation, time 
period, stage and comorbidity for patients with colon cancer 
[Includes only patients who didn’t have surgery; n=7647] 
 Number (%) 
receiving 
chemotherapy 
Unadjusted 
(n=7647) 
Mutually adjusted 
(n=7644) 
 n % OR 95% CI p OR 95% CI p 
Age group 1589 20.8   <0.001   <0.001 
<60 years 450 62.2 1.00   1.00   
60-69 years 500 42.3 0.44 0.37, 0.54 <0.001 0.43 0.35, 0.52 <0.001 
70-79 years 520 22.8 0.18 0.15, 0.21 <0.001 0.20 0.17, 0.24 <0.001 
80+ years 119 3.4 0.02 0.02, 0.03 <0.001 0.03 0.02, 0.04 <0.001 
         
Sex 1589    <0.001   <0.001 
Female 607 15.6 1.00   1.00   
Male 982 26.1 1.90 1.70, 2.13 <0.001 1.40 1.22, 1.61 <0.001 
         
Deprivation quintile 1589    <0.001   <0.001 
1 (least deprived) 320 28.9 1.00   1.00   
2 304 22.5 0.71 0.59, 0.86 <0.001 0.79 0.63, 0.99 0.037 
3 316 21.9 0.69 0.58, 0.83 <0.001 0.67 0.54, 0.84 <0.001 
4 316 18.6 0.56 0.47, 0.67 <0.001 0.62 0.50, 0.78 <0.001 
5 333 16.3 0.48 0.40, 0.57 <0.001 0.44 0.36, 0.55 <0.001 
         
Period of diagnosis 1589    <0.001   <0.001 
1999-2002 331 16.4 1.00   1.00   
2003-2006 559 19.8 1.26 1.09, 1.47 0.003 1.42 1.18, 1.70 <0.001 
2007-2010 739 24.6 1.67 1.44, 1.93 <0.001 2.42 2.01, 2.90 <0.001 
         
Stage 1589    <0.001   <0.001 
I 2 6.5 1.00   1.00   
II 9 11.4 1.86 0.38, 9.16 0.443 2.15 0.41, 11.4 0.369 
III 43 38.4 9.04 2.05, 39.8 0.004 7.10 1.50, 33.9 0.014 
IV 1406 31.3 6.61 1.58, 27.8 0.10 4.20 0.94, 18.7 0.060 
Unstaged 126 4.3 0.65 0.15, 2.76 0.560 0.72 0.16, 3.25 0.671 
Stage PT 3 100.0 -      
         
CCM 1589    <0.001   <0.001 
0 1172 25.3 1.00   1.00   
1-2 100 12.2 0.41 0.33, 0.51 <0.001 0.68 0.553 0.87 0.002 
3+ 19 7.4 0.24 0.15, 0.38 <0.001 0.30 0.18, 0.51 <0.001 
No HES link 298 15.4 0.54 0.47, 0.62 <0.001 0.60 0.50, 0.72 <0.001 
         
 
 
